All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

desflurane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
halogenated compounds used as general inhalation anaesthetics	811	57041-67-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: Difluoromethyl 1,2,2,2-tetrafluoroethyl ether desflurane	A fluorinated ether that is used as a volatile anesthetic for maintenance of general anesthesia. Molecular weight: 168.04 Formula: C3H2F6O CLOGP: 1.51 LIPINSKI: 0 HAC: 1 HDO: 0 TPSA: 9.23 ALOGS: -1.68 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 18, 1992	FDA	BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Serotonin syndrome	83.38	40.14	29	1244	24684	50579167
Procedural hypotension	79.52	40.14	15	1258	1087	50602764
Neuromuscular block prolonged	77.03	40.14	13	1260	498	50603353
Bradycardia	68.46	40.14	33	1240	64393	50539458
Cardiac arrest	65.93	40.14	35	1238	83616	50520235
Hyperthermia malignant	65.72	40.14	12	1261	727	50603124
Anaphylactic shock	61.64	40.14	22	1251	20133	50583718
Anaphylactic reaction	58.34	40.14	28	1245	54027	50549824
Delayed recovery from anaesthesia	46.57	40.14	9	1264	740	50603111
Vitamin K deficiency	45.02	40.14	8	1265	415	50603436
Bronchospasm	44.58	40.14	16	1257	14838	50589013
Unwanted awareness during anaesthesia	41.21	40.14	7	1266	278	50603573

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	168.92	44.05	32	981	1752	29571762
Anaphylactic shock	104.93	44.05	32	981	13304	29560210
Seizure like phenomena	89.99	44.05	16	997	610	29572904
Serotonin syndrome	72.92	44.05	26	987	17486	29556028
Bronchospasm	58.56	44.05	19	994	9590	29563924
Neuromuscular block prolonged	48.13	44.05	9	1004	454	29573060
Anticholinergic syndrome	47.97	44.05	10	1003	884	29572630

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperthermia malignant	215.10	34.96	42	2403	2417	64493870
Serotonin syndrome	145.58	34.96	55	2390	39227	64457060
Anaphylactic shock	144.07	34.96	51	2394	30277	64466010
Neuromuscular block prolonged	118.65	34.96	22	2423	955	64495332
Bronchospasm	97.36	34.96	35	2410	21647	64474640
Post procedural complication	90.38	34.96	33	2412	21320	64474967
Cardiac arrest	79.24	34.96	57	2388	154007	64342280
Bradycardia	77.95	34.96	51	2394	118168	64378119
Anaphylactic reaction	74.94	34.96	41	2404	68623	64427664
Delayed recovery from anaesthesia	74.05	34.96	16	2429	1512	64494775
Seizure like phenomena	72.81	34.96	16	2429	1636	64494651
Procedural hypotension	70.70	34.96	16	2429	1870	64494417
Anticholinergic syndrome	60.13	34.96	15	2430	2654	64493633
Trigemino-cardiac reflex	52.95	34.96	9	2436	235	64496052
Drug interaction	51.94	34.96	66	2379	362017	64134270
Circulatory collapse	47.76	34.96	24	2421	33708	64462579
Hypotension	47.75	34.96	65	2380	380909	64115378
Recurrence of neuromuscular blockade	47.55	34.96	8	2437	196	64496091
Laryngospasm	46.97	34.96	13	2432	3432	64492855
End-tidal CO2 increased	38.50	34.96	5	2440	17	64496270
Unwanted awareness during anaesthesia	38.34	34.96	7	2438	278	64496009
Procedural vomiting	38.01	34.96	8	2437	666	64495621
Vitamin K deficiency	37.95	34.96	8	2437	671	64495616
Procedural nausea	37.78	34.96	8	2437	686	64495601
Subcutaneous emphysema	36.03	34.96	9	2436	1600	64494687

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N01AB07	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Halogenated hydrocarbons
CHEBI has role	CHEBI:38870	inhalation anesthetics
MeSH PA	D000777	Anesthetics
MeSH PA	D018685	Anesthetics, Inhalation
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
FDA EPC	N0000175681	General Anesthetic
FDA PE	N0000175975	General Anesthesia

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Hyperkalemia	contraindication	14140009
Cirrhosis of liver	contraindication	19943007	DOID:5082
Viral hepatitis C	contraindication	50711007	DOID:1883
Viral hepatitis type B	contraindication	66071002	DOID:2043
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Duchenne muscular dystrophy	contraindication	76670001	DOID:11723
Myasthenia gravis	contraindication	91637004	DOID:437
Disease of liver	contraindication	235856003	DOID:409
Neuromyopathy	contraindication	255522009	DOID:440
Familial periodic paralysis	contraindication	267607008	DOID:1029
Lesion of brain	contraindication	301766008
Malignant hyperthermia	contraindication	405501007
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN	OPENER				CHEMBL	CHEMBL
Potassium channel subfamily K member 3	Ion channel	O14649	KCNK3_HUMAN	OPENER				CHEMBL	CHEMBL
Potassium channel subfamily K member 9	Ion channel	Q9NPC2	KCNK9_HUMAN	OPENER				CHEMBL	CHEMBL
Potassium channel subfamily K member 10	Ion channel	P57789	KCNKA_HUMAN	OPENER				CHEMBL	CHEMBL
Potassium channel subfamily K member 18	Ion channel	Q7Z418	KCNKI_HUMAN	OPENER				CHEMBL	CHEMBL
Glycine receptor (alpha-1/beta)	Ion channel	P23415 P48167	GLRA1_HUMAN GLRB_HUMAN	POSITIVE MODULATOR				CHEMBL	CHEMBL
GABA-A receptor; anion channel	Ion channel	O00591 O14764 P14867 P18505 P18507 P28472 P31644 P34903 P47869 P47870 P48169 P78334 Q16445 Q8N1C3 Q99928 Q9UN88	GBRP_HUMAN GBRD_HUMAN GBRA1_HUMAN GBRB1_HUMAN GBRG2_HUMAN GBRB3_HUMAN GBRA5_HUMAN GBRA3_HUMAN GBRA2_HUMAN GBRB2_HUMAN GBRA4_HUMAN GBRE_HUMAN GBRA6_HUMAN GBRG1_HUMAN GBRG3_HUMAN GBRT_HUMAN	POSITIVE ALLOSTERIC MODULATOR				CHEMBL	CHEMBL

External reference:

ID	Source
4020649	VUID
N0000148295	NUI
D00546	KEGG_DRUG
27340	RXNORM
4020649	VANDF
C0063252	UMLSCUI
CHEBI:4445	CHEBI
DSF	PDB_CHEM_ID
CHEMBL1200733	ChEMBL_ID
DB01189	DRUGBANK_ID
D000077335	MESH_DESCRIPTOR_UI
42113	PUBCHEM_CID
6505	INN_ID
7156	IUPHAR_LIGAND_ID
CRS35BZ94Q	UNII
247482	MMSL
4545	MMSL
d02374	MMSL
004114	NDDF
108393001	SNOMEDCT_US
386841003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9961	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	23 sections
Desflurane	HUMAN PRESCRIPTION DRUG LABEL	1	0781-6172	LIQUID	240 mL	RESPIRATORY (INHALATION)	ANDA	27 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	26 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	10019-644	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	27 sections
SUPRANE	HUMAN PRESCRIPTION DRUG LABEL	1	10019-646	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	26 sections
Suprane	HUMAN PRESCRIPTION DRUG LABEL	1	52584-641	LIQUID	240 mL	RESPIRATORY (INHALATION)	NDA	23 sections